SCHEMBL9010501

SCHEMBL9010501

C=CCn1cnc2c1c(=O)[nH]c(=O)n2C

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 2/20 0.62
MAPK1 P28482 2/20 0.59
CYP3A4 P08684 1/20 0.59
PMP22 Q01453 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.57
LMNA P02545 2/20 0.56
POLB P06746 2/20 0.56
KDM4E B2RXH2 1/20 0.56
PDE4A P27815 4/20 0.52
ADORA2A P29274 4/20 0.52
PDE4B Q07343 4/20 0.52
PDE4C Q08493 4/20 0.52
PDE4D Q08499 4/20 0.52
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
PKM P14618 1/20 0.48
BRD4 O60885 1/20 0.48
BRD2 P25440 1/20 0.48
BRD3 Q15059 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10346511 0.87 SMN1; SMN2 (0.60) ADORA2BMAPK1CYP3A4PMP22SMN1; SMN2
SCHEMBL10335171 0.87 MAPK1 (0.60) ADORA2BMAPK1CYP3A4PMP22SMN1; SMN2
SCHEMBL11462219 0.85 MAPK1 (0.62) ADORA2BMAPK1CYP3A4PMP22SMN1; SMN2
SCHEMBL11472384 0.85 MAPK1 (0.62) ADORA2BMAPK1CYP3A4PMP22SMN1; SMN2
SCHEMBL27954170 0.84 MAPK1 (0.57) MAPK1CYP3A4PMP22SMN1; SMN2LMNA
SCHEMBL7519416 0.84 PDE4A (0.56) ADORA2BMAPK1LMNAPOLBKDM4E
SCHEMBL8431107 0.84 MAPK1 (0.61) ADORA2BMAPK1CYP3A4PMP22SMN1; SMN2
SCHEMBL10955005 0.84 MAPK1 (0.64) MAPK1CYP3A4PMP22SMN1; SMN2LMNA
SCHEMBL9055277 0.83 PDE4A (0.61) ADORA2BPDE4AADORA2APDE4BPDE4C
SCHEMBL27954165 0.83 MAPK1 (0.56) ADORA2BMAPK1CYP3A4PMP22SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5550041-A PRODUCING 3-METHYL-7-ALKYLXANTHINE BY CULTIVATING PSEUDOMONAS TRANSFORMED TO PRODUCE CAFFEINE DEMETHYLASE IN NUTRIENT MEDIUM CONTAINING 1,3-DIMETHYL-7-ALKYLXANTHINE AMANO PHARMACEUTICAL CO., LTD. (JP) 1996-08-27 US claimed
JP-6133779-A None JP disclosed
JP-5317071-A None JP disclosed
US-7902205-B2 Purinone derivatives as HM74A agonists INCYTE CORPORATION (US) 2011-03-08 US disclosed
US-7863285-B2 Purinone derivatives as HM74A agonists INCYTE CORPORATION (US) 2011-01-04 US disclosed
US-20090088446-A1 PURINONE DERIVATIVES AS HM74A AGONISTS INCYTE CORPORATION (US) 2009-04-02 US disclosed
US-20090076269-A1 PURINONE DERIVATIVES AS HM74A AGONISTS INCYTE CORPORATION (US) 2009-03-19 US disclosed
US-7462624-B2 Purinone derivatives as HM74a agonists INCYTE CORPORATION (US) 2008-12-09 US disclosed
US-20080045555-A1 PURINONE DERIVATIVES AS HM74A AGONISTS INCYTE CORPORATION (US) 2008-02-21 US disclosed
CN-1143115-A Method for producing 3-methyl-7-alkyl-yellow purine micro-organism AMANO PHARMA CO LTD (JP) 1997-02-19 CN disclosed
US-5550041-A PRODUCING 3-METHYL-7-ALKYLXANTHINE BY CULTIVATING PSEUDOMONAS TRANSFORMED TO PRODUCE CAFFEINE DEMETHYLASE IN NUTRIENT MEDIUM CONTAINING 1,3-DIMETHYL-7-ALKYLXANTHINE AMANO PHARMACEUTICAL CO., LTD. (JP) 1996-08-27 US disclosed
US-5550041-A PRODUCING 3-METHYL-7-ALKYLXANTHINE BY CULTIVATING PSEUDOMONAS TRANSFORMED TO PRODUCE CAFFEINE DEMETHYLASE IN NUTRIENT MEDIUM CONTAINING 1,3-DIMETHYL-7-ALKYLXANTHINE AMANO PHARMACEUTICAL CO., LTD. (JP) 1996-08-27 US disclosed
JP-H06133779-A NEW DNA COMPOUND AND PRODUCTION OF 3-METHYL-7-ALKYLXANTHINE BY RECOMBINANT PRODUCED BY USING THE COMPOUND AMANO PHARMACEUT CO LTD 1994-05-17 JP disclosed
JP-H05317071-A PRODUCTION OF 3-METHYL-7-ALKYLXANTHINE BY USING MICROORGANISM AMANO PHARMACEUT CO LTD 1993-12-03 JP disclosed
EP-0570831-A2 Use of Xanthinderivatives for treatment of cerebral nerve dammages after disruption of the blood circulation HOECHST AKTIENGESELLSCHAFT (DE) 1993-11-24 EP disclosed
US-5109003-A METHOD FOR THE TREATMENT OF PEPTIC ULCER DISEASE HOECHST JAPAN LIMITED (JP) 1992-04-28 US disclosed
US-5082845-A Gastrointestinal HOECHST JAPAN LIMITED (JP) 1992-01-21 US disclosed
EP-0330031-B1 THERAPEUTIC AGENTS FOR THE TREATMENT OF PEPTIC ULCER DISEASE HOECHST JAPAN LIMITED (JP) 1991-12-11 EP disclosed
EP-0413278-A2 Use of xanthine derivatives against peptic ulcers HOECHST JAPAN LIMITED (JP) 1991-02-20 EP disclosed
EP-0330031-A1 Therapeutic agents for the treatment of peptic ulcer disease HOECHST JAPAN LIMITED (JP) 1989-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088446-A1 PURINONE DERIVATIVES AS HM74A AGONISTS GPR84, P2RY1, ADRA1A ADORA2B 68/4885MAPK1 2786/4885CYP3A4 1580/4885
US-20090076269-A1 PURINONE DERIVATIVES AS HM74A AGONISTS GPR84, P2RY1, ADRA1A ADORA2B 68/4885MAPK1 2786/4885CYP3A4 1580/4885
US-20080045555-A1 PURINONE DERIVATIVES AS HM74A AGONISTS GPR84, P2RY1, ADRA1A ADORA2B 68/4885MAPK1 2786/4885CYP3A4 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.